Risks
4 risks
Risk Intelligence
Asia branded business degrowth
View Risks →Ajanta Pharma Limited — Q3 FY26
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,375 crore (+20% YoY) and EBITDA of ₹382 crore (+19% YoY), driven by robust US generics (+52% YoY) and India branded (+19% YoY) growth.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,375 crore (+20% YoY) and EBITDA of ₹382 crore (+19% YoY), driven by robust US generics (+52% YoY) and India branded (+19% YoY) growth. The US business benefited from eight new product launches and market share gains, while India outperformed IPM by 28%. Africa branded grew 33% YoY, but Asia branded declined 9% YoY due to softer traction in certain markets. Management maintained EBITDA margin guidance of 27%±1% for FY26, with gross margins expected around 78%±1%. The company added 150 MRs in India and plans to launch GLP-1 products in March 2026 via a partnership with Bioon. Key risk: Asia branded recovery may be slower than expected if shipment delays persist.
अजंता फार्मा की तीसरी तिमाही (अक्टूबर-दिसंबर 2025) में कमाई ₹1,375 करोड़ रही, जो पिछले साल से 20% ज्यादा है। कंपनी का मुनाफा (EBITDA) ₹382 करोड़ (+19%) हुआ। अमेरिका में जेनेरिक दवाओं की बिक्री 52% बढ़ी, क्योंकि 8 नए उत्पाद लॉन्च हुए और बाजार हिस्सेदारी बढ़ी। भारत में ब्रांडेड दवाओं की बिक्री 19% बढ़ी, जो पूरे बाजार से 28% ज्यादा है। अफ्रीका में 33% बढ़ोतरी हुई, लेकिन एशिया में 9% गिरावट आई। कंपनी ने पूरे साल 27% मुनाफा मार्जिन और 78% सकल मार्जिन का अनुमान रखा है। भारत में 150 नए मेडिकल रिप्रेजेंटेटिव जोड़े गए। मार्च 2026 में Bioon के साथ मिलकर GLP-1 दवाएं लॉन्च करने की योजना है। खतरा: एशिया में शिपमेंट में देरी से वहां सुधार धीमा रह सकता है।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
US Generics Revenue
₹399 crore
+52% YoY
US generics revenue grew 52% YoY to ₹399 crore, driven by new launches and market share gains.
India Branded Growth (IQVIA)
11.4%
+2.5pp vs IPM
India branded business grew 11.4% as per IQVIA, outperforming IPM growth of 8.9%.
Africa Branded Revenue
₹230 crore
+33% YoY
Africa branded revenue grew 33% YoY to ₹230 crore, surpassing internal plans.
Medical Representative Count
3,750
+300 YTD
Total MR strength reached 3,750 with 300 additions in 9 months, supporting field expansion.
What Changed vs Last Quarter
NEW
GLP-1 launch in India in March 2026
Company plans to launch GLP-1 products in India under own brand in March 2026, being in the first wave.
UPDATED
FY26 EBITDA margin guidance of 27%±1%
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding forex mark-to-market impact.
UPDATED
FY26 gross margin guidance of 78%±1%
Gross margin expected to remain around 78%±1% for the full year.
UPDATED
FY26 capex guidance of ~₹300 crore
Capital expenditure for FY26 expected to be around ₹300 crore, with ₹235 crore spent in 9 months.
DROPPED
US generics growth to sustain at current run-rate
Management expects US generics to maintain the current quarterly run-rate of ~₹343 crore for the next two quarters.
DROPPED
Africa business upgraded to double-digit growth for FY26
Management upgraded Africa growth guidance from mid-single-digit to double-digit for the full year, citing favorable base effect.
NEW RISK
Asia branded business degrowth
Asia branded revenue declined 9% YoY in Q3 due to softer traction in certain markets and shipment delays.
NEW RISK
Competition in GLP-1 market in India
Analyst raised concern about intense competition in India GLP-1 market with 15-20+ players expected; management acknowledged but expects lower competition in emerging markets.
NEW RISK
Forex volatility impact
9-month forex mark-to-market loss of ₹61 crore under other expenses, though no loss in Q3; currency movements remain a risk.
NEW RISK
New labor code cost impact
Additional provision of ₹7 crore made for new labor code liabilities; ongoing impact on staff costs.
RISK GONE
Forex volatility impacting reported margins
Mark-to-market forex losses of ₹41 crore in Q2 distorted EBITDA margin; continued volatility could mask underlying margin performance.
RISK GONE
IQVIA data anomaly in cardiac segment
Management acknowledged a gap between IQVIA-reported growth (6%) and internal sales growth (matching IPM's 12%) in cardiac, which could affect investor perception.
RISK GONE
Africa business unpredictability from aid agency procurement
Africa institutional (antimalarial) business remains dependent on unpredictable aid agency procurement, with revenue declining 17% in H1.
RISK GONE
Working capital increase from factoring discontinuation
Trade receivables days increased to 101 from 94 due to switch from factoring to working capital loans, though management says it's P&L neutral.
Fast read
Guidance and risk preview
Management reiterated EBITDA margin guidance of 27%±1% for the full year, excluding forex mark-to-market impact.
Asia branded revenue declined 9% YoY in Q3 due to softer traction in certain markets and shipment delays.
View Risks →